Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of
severe and debilitating diseases.
Founded in 2002 in the United States, Alnylam is delivering on a bold vision to turn scientific possibility into reality for patients and our pioneering work has now delivered the world’s first approved RNAi therapeutics.
We are executing on our “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
We have five investigational medicines in late-stage clinical development and our goal is to start four clinical trials of new molecules each year until the end of 2025. In 2016, we established a commercial headquarter in Europe and we continue to invest responsibly to broaden our geographical footprint within the region, now employing over 300 people across multiple
countries including Portugal.

Our Vision
Harnessing a revolution in biology for human health®.

Our Mission
Build a top-tier, global, independent biopharmaceutical company founded on RNAi.

Our Core Values
Commitment to People, Innovation & Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.